Central nervous system effects of subdissociative doses of (S)‐ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Clinical pharmacology and therapy

• Publication date

  1995-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0009-9236(95)90194-9PMID 7648766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A preliminary evaluation of the scanditronix PC2048-15B brain scanner

  2004cited by this paper
• Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization.

  1995cited by this paper
• Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET).

  1994cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper
• Cerebral pharmacodynamics of anaesthetic and subanaesthetic doses of ketamine in the normoventilated pig

  1993cited by this paper
• Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.

  1992cited by this paper
• NMDA receptor antagonist MK‐801 blocks non‐opioid stress‐induced analgesia in the formalin test

  1992cited by this paper
• Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.

  1992cited by this paper
• Ketamine and midazolam decrease cerebral blood flow and consequently their own rate of transport to the brain: An application of mass balance pharmacokinetics with a changing regional blood flow

  1992cited by this paper
• The NMDA receptor antagonist CPP abolishes neurogenic “wind-up pain” after intrathecal administration in humans.

  1992cited by this paper
• Uses and Limitations of Positron Emission Tomography in Clinical Pharmacokinetics/Dynamics (Part I)

  1992cited by this paper
• Uses and limitation of positron emission tomography in clinial pharmacokinetics/dynamics. I

  1992cited by this paper
• In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography.

  1991cited by this paper
• The chiral forms of ketamine as probes for NMDA receptor functions in humans

  1991cited by this paper
• The applications of PET in clinical oncology.

  1991cited by this paper
• A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography

  1990cited by this paper
• Performance characteristics of an eight-ring whole body PET scanner.

  1990cited by this paper
• Noncompetitive excitatory amino acid receptor antagonists.

  1990cited by this paper
• Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor.

  1990cited by this paper
• Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity.

  1988cited by this paper
• Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action

  1988cited by this paper
• In vivo characterization of myocardium muscarinic receptors by positron emission tomography.

  1981cited by this paper

• Cognitive and psychotic effects of ketamine "short- vs. long-term" therapy in a rat model of depression: Hippocampal TrkB/Akt/GSK-3β/mTOR/autophagy trajectories.

  2025cites this paper
• Esketamine: Less Drowsiness, More Analgesia

  2024cites this paper
• Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson’s Disease

  2024cites this paper
• Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment

  2023cites this paper
• Cellular consequences triggered by ketamine on exposure to human glioblastoma epithelial (LN‐229) cells

  2023cites this paper
• Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain

  2023cites this paper
• Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors

  2023cites this paper
• A Molecular Toolbox of Positron Emission Tomography Tracers for General Anesthesia Mechanism Research.

  2023cites this paper
• Nitrous Oxide, a Rapid Antidepressant, Has Ketamine-like Effects on Excitatory Transmission in the Adult Hippocampus.

  2022cites this paper
• Ketamine in Psychiatric Disorders

  2021cites this paper
• Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders

  2021cites this paper
• Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

  2021cites this paper
• Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics

  2020cites this paper
• A systematic review of ketamine for the treatment of depression among older adults

  2020cites this paper
• Procedural Sedation and Analgesia in Adults

  2019cites this paper
• Neurocognitive performance under combined regimens of ketamine-dexmedetomidine and ketamine-fentanyl in healthy adults: A randomised trial.

  2019cites this paper
• Ketamine applications beyond anesthesia - A literature review.

  2019cites this paper
• GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.

  2019cites this paper
• Side-effects associated with ketamine use in depression: a systematic review.

  2018cites this paper
• Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors.

  2018cites this paper
• Intravascular Ketamine Increases Theta-Burst but Not High Frequency Tetanus Induced LTP at CA3-CA1 Synapses Within Three Hours and Devoid of an Increase in Spine Density

  2018cites this paper
• Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy

  2018cites this paper
• First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors

  2018cites this paper
• Studying the synaptome: insights into ketamine action

  2018cites this paper
• Biomarkers, designs, and interpretations of resting‐state fMRI in translational pharmacological research: A review of state‐of‐the‐Art, challenges, and opportunities for studying brain chemistry

  2017cites this paper
• Classics in Chemical Neuroscience: Ketamine.

  2017cites this paper
• The use of ketamine in ECT anaesthesia: A systematic review and critical commentary on efficacy, cognitive, safety and seizure outcomes

  2017cites this paper
• Ketamine metabolites with antidepressant effects: Fast, economical, and eco‐friendly enantioselective separation based on supercritical‐fluid chromatography (SFC) and single quadrupole MS detection

  2017cites this paper
• Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?

  2017cites this paper
• Quantitative chiral and achiral determination of ketamine and its metabolites by LC‐MS/MS in human serum, urine and fecal samples

  2017cites this paper
• Ketamine: Neurotoxicity and Neurobehavioral Disorders

  2017cites this paper
• A REVIEW OF KETAMINE ABUSE AND DIVERSION

  2016cites this paper
• Ketamine: NMDA Receptors and Beyond

  2016cites this paper
• Low-Dose Ketamine in Chronic Critical Illness

  2016cites this paper
• Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial

  2016cites this paper
• The Effects of Ketamine on Cognitive Function in Elderly Patients Undergoing Ophthalmic Surgery: A Pilot Study

  2016cites this paper
• The effects of minimal-dose versus low-dose S-ketamine on opioid consumption, hyperalgesia, and postoperative delirium: a triple-blinded, randomized, active- and placebo-controlled clinical trial.

  2016cites this paper
• Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy

  2015cites this paper
• A subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades

  2015cites this paper
• Erratum to: a subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades

  2015cites this paper
• Application of cross-species PET imaging to assess neurotransmitter release in brain

  2015cites this paper
• Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function.

  2014influential citation
• Initial Evaluation of 18F-GE-179, a Putative PET Tracer for Activated N-Methyl d-Aspartate Receptors

  2014cites this paper
• Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression.

  2014cites this paper
• Initial Evaluation of 18 F-GE-179 , A Putative PET Tracer for Activated N-Methyl D-Aspartate Receptors

  2014cites this paper
• Sleep-Dependent Declarative Memory Consolidation—Unaffected after Blocking NMDA or AMPA Receptors but Enhanced by NMDA Coagonist D-Cycloserine

  2013cites this paper
• Radiosynthesis of carbon-11 and fluorine-18 labelled radiotracers to image the ionotropic and metabotropic glutamate receptors.

  2013cites this paper
• NEURAL CORRELATE OF VISUAL WORKING MEMORY IN THE MACAQUE MONKEY

  2013cites this paper
• Ketamine in Pain Management

  2013cites this paper
• Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

  2013cites this paper
• Glycine transport inhibitors in the treatment of schizophrenia.

  2012cites this paper
• NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.

  2012cites this paper
• The role of setting for ketamine abuse: clinical and preclinical evidence

  2012cites this paper
• Glycine transporter-1: a new potential therapeutic target for schizophrenia.

  2011cites this paper
• Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral Mu antagonists.

  2011cites this paper
• Transmucosal nasal drug delivery : pharmacokinetics and pharmacodynamics of nasally applied esketamine

  2011cites this paper
• Intraoperative infusion of S(+)-ketamine enhances post-thoracotomy pain control compared with perioperative parecoxib when used in conjunction with thoracic paravertebral ropivacaine infusion.

  2011cites this paper
• Oral ketamine as a positive control in human abuse potential studies.

  2010cites this paper
• Taming the Ketamine Tiger

  2010cites this paper
• Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

  2010cites this paper
• A key role of the basal ganglia in pain and analgesia - insights gained through human functional imaging

  2010cites this paper
• Glycine Transport Inhibitors for the Treatment of Schizophrenia

  2010cites this paper
• PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development.

  2010cites this paper
• Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists.

  2009cites this paper
• Determination and toxicokinetics comparison of ketamine and S(+)-ketamine in dog plasma by HPLC-MS method.

  2009cites this paper
• Neuroimaging in Baboons

  2009cites this paper
• Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia

  2009cites this paper
• Pharmacology of Sedativ e -Analgesic Agents: Dexmedetomidine , Remifentanil,e Anesthetics , a nd the Role of Peripheral Mu Antagonists

  2009cites this paper
• The evolution of pain management in the critically ill trauma patient: Emerging concepts from the global war on terrorism

  2008cites this paper
• Molecular imaging with PET.

  2008cites this paper
• Kétamine marquée par deutérium

  2008cites this paper
• Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

  2007cites this paper
• Low-Dose Ketamine: Efficacy in Pediatric Sedation

  2007cites this paper
• Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans

  2007cites this paper
• An investigation of the acute and chronic effects of ketamine on cognition.

  2006cites this paper
• In vivo PET assay of functional P-gp in the blood-brain barrier

  2006cites this paper
• Critical review of KETAMINE

  2006cites this paper
• Evidence and methodology in clinical pain trials with special focus on ketamine

  2006cites this paper
• Biomarkers in early phase development of central nervous system drugs : a conceptual framework

  2006cites this paper
• Revising a Dogma: Ketamine for Patients with Neurological Injury?

  2005cites this paper
• Ischemic brain damage after ketamine and xylazine treatment in a young laboratory monkey (Macaca fascicularis).

  2005cites this paper
• Low‐dose ketamine failed to spare morphine after a remifentanil‐based anaesthesia for ear, nose and throat surgery

  2005cites this paper
• The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

  2005cites this paper
• Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.

  2005cites this paper
• Opioids Used in Primary Care for the Management of Pain: A Pharmacologic, Pharmacotherapeutic and Pharmacodynamic Overview

  2005cites this paper
• A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261.

  2004cites this paper
• [Club drugs: old medicines as new party drugs].

  2004cites this paper
• Pain relief by ketamine

  2004cites this paper
• Neuroimaging studies on ketamine

  2004cites this paper
• Improvement of Pain Treatment After Major Abdominal Surgery by Intravenous S(+)-Ketamine

  2004cites this paper
• Club drugs: los viejos fármacos son las nuevas drogas de la fiesta

  2004cites this paper
• Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

  2003cites this paper
• Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor.

  2003cites this paper
• Anesthesia Meets Memory

  2003cites this paper
• EFFECT OF LONG-TERM KETAMINE ADMINISTRATION ON VOCALIZATION TO PAW PRESSURE AND ON SPINAL WIND-UP ACTIVITY IN MONOARTHRITIC RATS

  2003cites this paper
• Determination of the enantiomers of ketamine and norketamine in human plasma by enantioselective liquid chromatography-mass spectrometry.

  2003cites this paper
• Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers.

  2002cites this paper
• The Recruitment of Normal Healthy Volunteers: A Review of The Literature on the Use of Financial Incentives

  2002cites this paper
• Cognitive Impairment after Small-dose Ketamine Isomers in Comparison to Equianalgesic Racemic Ketamine in Human Volunteers

  2002cites this paper
• SYNTHESIS AND IN VITRO AND IN VIVO EVALUATION OF [11C]METHYL-BIII277CL FOR IMAGING THE PCP-BINDING SITE OF THE NMDA RECEPTOR BY PET

  2002cites this paper